Dermatology
| Fingernail psoriasis and PsA
Dermatology
Fingernail psoriasis and PsA

Ixekizumab improves nail and skin lesions in patients with active psoriatic arthritis and prior TNF-inhibitor inadequate response: 3-year results from spirit-p2

book_2 Source: EADV Virtual - Poster session
calendar_today Published on Medfyle: November 2020
headphones 3 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • There is a significant correlation between fingernail psoriasis and PsA.
  • Ixekizumab is a high-affinity monoclonal antibody that targets IL-17A.
  • In TNF-IR active PsA, ixekizumab delivered reduced and cleared skin and nail lesions over 3 years.
  • Results of the 3-year analysis from SPIRIT-P2 are consistent with previous studies.
Presenting Author
Read more arrow_downward Hide arrow_upward

April W. Armstrong, MD, MPH
Department of Dermatology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA

Dr. April Armstrong is Associate Dean of Clinical Research at Keck School of Medicine at USC. She also serves as Director of Clinical Research for the Southern California Clinical and Translational Research Institute (SC CTSI). In the Department of Dermatology at USC, she serves as Vice Chair, Director of Clinical Trials and Outcomes Research, and Director of the Psoriasis Program.

Author disclosures
Read more arrow_downward Hide arrow_upward

A. W. Armstrong has been an investigator, advisor, and/or speaker for: AbbVie, Celgene, Eli Lilly and Company, Janssen, Novartis, Regeneron, Sanofi, and Valeant Pharmaceuticals;


Feedback